TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07637981: Double-blind, Randomised, Placebo-controlled Phase 1/2a Study of Safety, Tolerability and PK of Single and Repeated SC Doses of DX243 in Healthy Volunteers, and 1-month Safety and Efficacy in Moderately Severe Age-relate

Sponsor: Dendrogenix · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 24 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$3,950,800

Rescue Site Savings

+$2,622,800

Unlock Full NCT07637981 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07637981 Rescue Dossier →